Incorporation of Edited MRS into Clinical Practice May Improve Care of Patients with IDH-Mutant Glioma

References

1. 1.↵
   1. Louis DN,
   2. Perry A,
   3. Wesseling P, et al

   . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23:1231–51 doi:10.1093/neuonc/noab106 pmid:34185076

   CrossRefPubMed
2. 2.↵
   1. Brat DJ,
   2. Verhaak RG,
   3. Aldape KD, et al

   ; Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015;372:2481–98 doi:10.1056/NEJMoa1402121 pmid:26061751

   CrossRefPubMed
3. 3.↵
   1. Labussière M,
   2. Idbaih A,
   3. Wang XW, et al

   . All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 2010;74:1886–90 doi:10.1212/WNL.0b013e3181e1cf3a pmid:20427748

   CrossRefPubMed
4. 4.↵
   1. Weller M,
   2. Van Den Bent M,
   3. Preusser M, et al

   . EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021;18:170–86 doi:10.1038/s41571-020-00447-z pmid:33293629

   CrossRefPubMed
5. 5.↵
   1. Mellinghoff IK,
   2. Van Den Bent MJ,
   3. Blumenthal DT, et al

   ; INDIGO Trial Investigators. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med 2023;389:589–60 doi:10.1056/NEJMoa2304194 pmid:37272516

   CrossRefPubMed
6. 6.↵
   1. Li Y,
   2. Qin Q,
   3. Zhang Y, et al

   . Noninvasive determination of the IDH status of gliomas using MRI and MRI-based radiomics: impact on diagnosis and prognosis. Curr Oncol 2022;29:6893–907 doi:10.3390/curroncol29100542 pmid:36290819

   CrossRefPubMed
7. 7.↵
   1. Karabacak M,
   2. Ozkara BB,
   3. Mordag S, et al

   . Deep learning for prediction of isocitrate dehydrogenase mutation in gliomas: a critical approach, systematic review and meta-analysis of the diagnostic test performance using a Bayesian approach. Quant Imaging Med Surg 2022;12:4033–46 doi:10.21037/qims-22-34 pmid:35919062

   CrossRefPubMed
8. 8.↵
   1. Pope WB,
   2. Prins RM,
   3. Albert Thomas M, et al

   . Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol 2012;107:197–205 doi:10.1007/s11060-011-0737-8 pmid:22015945

   CrossRefPubMed
9. 9.↵
   1. Choi C,
   2. Ganji SK,
   3. DeBerardinis RJ, et al

   . 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012;18:624–29 doi:10.1038/nm.2682 pmid:22281806

   CrossRefPubMed
10. 10.↵
    1. Andronesi OC,
    2. Kim GS,
    3. Gerstner E, et al

    . Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 2012;4:116ra4 doi:10.1126/scitranslmed.3002693 pmid:22238332

    Abstract/FREE Full Text
11. 11.↵
    1. Dang L,
    2. White DW,
    3. Gross S, et al

    . Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739–44 doi:10.1038/nature08617 pmid:19935646

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Batchala PP,
    2. Muttikkal TJ,
    3. Donahue JH, et al

    . Neuroimaging-based classification algorithm for predicting 1p/19q-codeletion status in IDH-mutant lower grade gliomas. AJNR Am J Neuroradiol 2019;40:426–32 doi:10.3174/ajnr.A5957 pmid:30705071

    Abstract/FREE Full Text
13. 13.↵
    1. Lasocki A,
    2. Buckland ME,
    3. Molinaro T, et al

    . Correlating MRI features with additional genetic markers and patient survival in histological grade 2-3 IDH-mutant astrocytomas. Neuroradiology 2023;65:1215–23 doi:10.1007/s00234-023-03175-0 pmid:37316586

    CrossRefPubMed
14. 14.↵
    1. Joyner DA,
    2. Garrett J,
    3. Batchala PP, et al

    . MRI features predict tumor grade in isocitrate dehydrogenase (IDH)–mutant astrocytoma and oligodendroglioma. Neuroradiology 2023;65:121–29 doi:10.1007/s00234-022-03038-0 pmid:35953567

    CrossRefPubMed
15. 15.↵
    1. Suchorska B,
    2. Giese A,
    3. Biczok A, et al

    . Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. Neuro Oncol 2018;20:279–88 doi:10.1093/neuonc/nox153 pmid:29016996

    CrossRefPubMed
16. 16.↵
    1. Jiang S,
    2. Zou T,
    3. Eberhart CG, et al

    . Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI: predicting IDH status with APTw MRI. Magn Reson Med 2017;78:1100–09 doi:10.1002/mrm.26820 pmid:28714279

    CrossRefPubMed
17. 17.↵
    1. Branzoli F,
    2. Deelchand DK,
    3. Sanson M, et al

    . In vivo ¹H MRS detection of cystathionine in human brain tumors. Magn Reson Med 2019;82:1259–65 doi:10.1002/mrm.27810 pmid:31131476

    CrossRefPubMed
18. 18.↵
    1. Branzoli F,
    2. Pontoizeau C,
    3. Tchara L, et al

    . Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy. Neuro Oncol 2019;21:765–74 doi:10.1093/neuonc/noz031 pmid:30726924

    CrossRefPubMed
19. 19.↵
    1. Branzoli F,
    2. Marjańska M

    . Magnetic resonance spectroscopy of isocitrate dehydrogenase mutated gliomas: current knowledge on the neurochemical profile. Curr Opin Neurol 2020;33:413–21 doi:10.1097/WCO.0000000000000833 pmid:32657882

    CrossRefPubMed
20. 20.↵
    1. Kim H,
    2. Kim S,
    3. Lee HH, et al

    . In-vivo proton magnetic resonance spectroscopy of 2-hydroxyglutarate in isocitrate dehydrogenase-mutated gliomas: a technical review for neuroradiologists. Korean J Radiol 2016;17:620–32 doi:10.3348/kjr.2016.17.5.620 pmid:27587950

    CrossRefPubMed
21. 21.↵
    1. Branzoli F,
    2. Deelchand DK,
    3. Liserre R, et al

    . The influence of cystathionine on neurochemical quantification in brain tumor in vivo MR spectroscopy. Magn Reson Med 2022;88:537–45 doi:10.1002/mrm.29252 pmid:35381117

    CrossRefPubMed
22. 22.↵
    1. Branzoli F,
    2. Liserre R,
    3. Deelchand DK, et al

    . Neurochemical differences between 1p/19q codeleted and noncodeleted IDH-mutant gliomas by in vivo MR spectroscopy. Radiology 2023;308:e223255 doi:10.1148/radiol.223255 pmid:37668523

    CrossRefPubMed
23. 23.↵
    1. Hervey-Jumper SL,
    2. Zhang Y,
    3. Phillips JJ, et al

    . Interactive effects of molecular, therapeutic, and patient factors on outcome of diffuse low-grade glioma. J Clin Oncol 2023;41:2029–42 doi:10.1200/JCO.21.02929 pmid:36599113

    CrossRefPubMed
24. 24.↵
    1. Choi I,
    2. Andronesi OC,
    3. Barker P, et al

    . Spectral editing in ¹H magnetic resonance spectroscopy: experts’ consensus recommendations. NMR Biomed 2021;34:e4411 doi:10.1002/nbm.4411 pmid:32946145

    CrossRefPubMed
25. 25.↵
    1. Branzoli F,
    2. Di Stefano AL,
    3. Capelle L, et al

    . Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy. Neuro Oncol 2018;20:907–16 doi:10.1093/neuonc/nox214 pmid:29126125

    CrossRefPubMed
26. 26.↵
    1. van den Bent MJ,
    2. Wefel JS,
    3. Schiff D, et al

    . Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011;12:583–93 doi:10.1016/S1470-2045(11)70057-2 pmid:21474379

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Von Elm E,
    2. Altman DG,
    3. Egger M, et al

    ; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453–57 doi:10.1016/S0140-6736(07)61602-X pmid:18064739

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Tkác I,
    2. Starcuk Z,
    3. Choi IY, et al

    . In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn Reson Med 1999;41:649–56 doi:10.1002/(SICI)1522-2594(199904)41:4<649::AID-MRM2>3.0.CO;2-G

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Di Stefano AL,
    2. Nichelli L,
    3. Berzero G, et al

    . In vivo 2-hydroxyglutarate monitoring with edited MR spectroscopy for the follow-up of IDH-mutant diffuse gliomas: the IDASPE Prospective Study. Neurology 2023;100:e94–106 doi:10.1212/WNL.0000000000201137 pmid:36180241

    Abstract/FREE Full Text
30. 30.↵
    1. De Godoy LL,
    2. Lim KC,
    3. Rajan A, et al

    . Non-invasive assessment of isocitrate dehydrogenase-mutant gliomas using optimized proton magnetic resonance spectroscopy on a routine clinical 3-Tesla MRI. Cancers (Basel) 2023;15:4453 doi:10.3390/cancers15184453 pmid:37760422

    CrossRefPubMed
31. 31.↵
    1. Tietze A,
    2. Choi C,
    3. Mickey B, et al

    . Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. J Neurosurg 2018;128:391–98 doi:10.3171/2016.10.JNS161793 pmid:28298040

    CrossRefPubMed
32. 32.↵
    1. Cuccarini V,
    2. Antelmi L,
    3. Pollo B, et al

    . In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting. Neurol Sci 2020;41:347–55 doi:10.1007/s10072-019-04087-9 pmid:31650436

    CrossRefPubMed
33. 33.↵
    1. Suh CH,
    2. Kim HS,
    3. Paik W, et al

    . False-positive measurement at 2-hydroxyglutarate MR spectroscopy in isocitrate dehydrogenase wild-type glioblastoma: a multifactorial analysis. Radiology 2019;291:752–62 doi:10.1148/radiol.2019182200 pmid:30990380

    CrossRefPubMed
34. 34.↵
    1. Nguyen TB,
    2. Melkus G,
    3. Taccone M, et al

    . Preoperative determination of isocitrate dehydrogenase mutation in gliomas using spectral editing MR: a prospective study. J Magn Reson Imaging 2021;53:416–26 doi:10.1002/jmri.27366 pmid:32940938

    CrossRefPubMed
35. 35.↵
    1. Reyes-Botero G,
    2. Giry M,
    3. Mokhtari K, et al

    . Molecular analysis of diffuse intrinsic brainstem gliomas in adults. J Neurooncol 2014;116:405–11 doi:10.1007/s11060-013-1312-2 pmid:24242757

    CrossRefPubMed
36. 36.↵
    1. Liserre R,
    2. Branzoli F,
    3. Pagani F, et al

    . Exceptionally rare IDH1-mutant adult medulloblastoma with concurrent GNAS mutation revealed by in vivo magnetic resonance spectroscopy and deep sequencing. Acta Neuropathol Commun 2023;11:47 doi:10.1186/s40478-023-01531-y pmid:36941703

    CrossRefPubMed
37. 37.↵
    1. Andronesi OC,
    2. Arrillaga-Romany IC,
    3. Ly KI, et al

    . Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun 2018;9:1474 doi:10.1038/s41467-018-03905-6 pmid:29662077

    CrossRefPubMed
38. 38.↵
    1. Andronesi OC,
    2. Loebel F,
    3. Bogner W, et al

    . Treatment response assessment in IDH-mutant glioma patients by noninvasive 3D functional spectroscopic mapping of 2-hydroxyglutarate. Clin Cancer Res Off Res 2016;22:1632–41 doi:10.1158/1078-0432.CCR-15-0656 pmid:26534967

    CrossRefPubMed
39. 39.↵
    1. Martel AL,
    2. Abolmaesumi P,
    3. Stoyanov D, et al

    1. Bolan PJ,
    2. Branzoli F D,
    3. Stefano AL, et al

    . Automated Acquisition Planning for Magnetic Resonance Spectroscopy in Brain Cancer. In: Martel AL, Abolmaesumi P, Stoyanov D, et al. eds. Medical Image Computing and Computer Assisted Intervention, 2020. October 4–8, 2020; Lima, Peru; Virtual